מתוך medicontext.co.il
WESTPORT, CT (Reuters Health) – High levels of interleukin (IL)-10 production in rheumatoid arthritis patients may protect against the progression of joint destruction, according to researchers in the Netherlands.
Dr. Catharina M. Verhoef, of University Medical Centre Utrecht, and colleagues examined levels of IL-10, IL-4 and interferon (IFN)-gamma production in relation to disease progression in 14 rheumatoid arthritis patients with mild disease and 23 with severe disease. As reported in the September issue of The Journal of Rheumatology, disease duration ranged from 5 to 15 years.
Of the three markers, only IL-10 differed significantly between the two groups of patients. Patients with mild disease had significantly higher levels of IL-10 produced ex vivo by peripheral blood mononuclear cells than did patients with severe disease. Also, taking all patients together, 48-hour ex vivo IL-10 production by peripheral blood mononuclear cells was significantly and negatively correlated with radiographic joint damage (p < 0.001).
The investigators were somewhat surprised to find no correlations between IL-4, IFN-gamma and joint destruction, they say. Both cytokines have been linked to disease processes in RA patients in the past.
On the other hand, the "study clearly shows a relation between ex vivo peripheral IL-10 production and severity of joint damage as well as disease activity in RA," Dr. Verhoef and colleagues say. "Assuming a beneficial influence for endogenous IL-10 suggests that IL-10 in general or produced by specific T-cell subsets might influence the course of RA," they conclude.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!